Urelumab

Product NameUrelumab
CAS934823-49-1
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)[1].

Biological Activity

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

in vivo

Urelumab (0.3-1 mg/kg, i.p., once every 3 days, 6 times) reduces the tumor volume and tumor weight in humanized 4-1BB mice^[2].
Urelumab (3-30 mg/kg, i.p., once every 3 days, 6 times) exhibits high safety in humanized 4-1BB mice^[2].

target

4-1BB

References

[1] John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520. DOI:10.1002/ajh.25757
[2] Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415. DOI:10.1186/s12967-022-03619-w